Drug Watch

Drug Watch

Introduction

The article discusses the use of platelet inhibitor, ticagrelor (Brilinta), approved by the Food and Drug Administration for curing Acute Coronary Syndrome (ACS). It discusses the implications of the medicines, and the reactions it could have if not administered properly.

Discussion

About the Article

Ticagrelor should be taken in combination with low quantities of aspirin (75 to 100 mg per day) to get to its required therapeutic result. If the daily dose of aspirin goes above 100 mg it will not be as effective as it should be. The drug and its major metabolite combined are lively substances and avert platelet aggregation. The drug helps decrease thrombotic cardiovascular proceedings. In its testing phases it reduced cardiovascular fatalities and MI in a more effective way than the alternate anti platelet drug of, clopidogrel (Plavix). The drug does however have a bigger risk of bleeding than its second option, and there is a higher chance of having dyspena when therapy starts. The risk appears to be put off as the use prolongs. During its initial phase of testing the ACS cure, ticagrelor, caused ventricular breaks in majority of the patients than the clopidogrel.

The drug is to be used twice a day. It is contra designated to patients with a record of intracranial hemorrhage, as it augments the chances of recurrent events. It is also advised for patients that have a record of rigorous bleeding and relentless hepatic mutilation. The drug is metabolized chiefly by cytochrome, and other protease inhibitors should be prevented as it can increase the level of the drugs, and the chances of bleeding. If these drugs are taken with a combination of ticagrelor they should not increase the dosage by forty mg.

The medical profile of the patient should be confirmed to ensure that other drugs that have the ...